Search

In the present work, the evolution of stress-induced martensite transformation under various deformation reductions was investigated, and the effects of martensite volume fractions on subsequent deformation behaviors were assessed. The cold rolling deformation was performed at ambient temperature, and the deformation reductions are 2%, 5%, and 10%, respectively. At a reduction of 2%, the presence of deformation bands and sparse martensite within the grains resulted in a yield strength of 545 MPa and an elongation of 16.3%. When the reduction was increased to 10%, a yield strength of 773 MPa and an elongation of 12.3% were observed. As stress increased, an increase in the martensite quantity and 5 types of martensitic variants are produced, which facilitated the accommodation of deformation. It was found that the volume fraction of martensite significantly influenced subsequent deformation behaviors. When the martensite volume fraction in the matrix is relatively low, the subsequent deformation process is primarily dominated by stress-induced martensite transformation. when the volume fraction is elevated, martensite twins predominantly manifest within the interior of the martensite, primarily exhibiting the {111}α'' type I twinning. When the martensitic transition approaches saturation, a significant occurrence of {130} a'' compound twinning is observed. The observed martensite and twin transformation indicate complex microstructure evolution during deformation. The multistage coordination of formed martensitic twins can effectively improve the properties. The results show that the regulation and control of martensite volume fraction can markedly affect the deformation behavior of metastable β titanium alloys.

Cytarabine is widely used in the treatment of hematological malignancies. Its common toxicities include myelosuppression and gastrointestinal disturbances. Additionally, it can cause central nervous system (CNS) symptoms, which include hoarseness, ataxic tremor, ataxic gait, nystagmus, dysmetria, and dysdiadochokinesia. In this article, we present the first case report of dysphonia, absent of CNS symptoms, induced by high-dose cytarabine (HiDAC) in a patient with acute myeloid leukemia. The patient’s voice began to change 3 days following the first cycle of HiDAC chemotherapy, and dysphonia recurred upon the reintroduction of HiDAC. To rule out other potential causes, a thorough examination and detailed medical history review were conducted, excluding factors such as vocal abuse, infection, effects of other medications, and underlying diseases as contributors to the dysphonia. The patient was diagnosed with HiDAC-induced dysphonia. This toxic effect was self-limiting, and the patient recovered in 10–15 days. Chemotherapy-induced dysphonia is a rarely reported and easily overlooked side effect. This adverse reaction is typically temporary and non-life-threatening; however, it substantially diminishes quality of life and may occasionally necessitate the discontinuation or postponement of chemotherapy. Physicians should be aware of this complication when administering chemotherapeutic agents.